AbbVie Inc. reports pharmaceutical developments across immunology, neuroscience, oncology and Allergan Aesthetics. Recurring updates include financial results by product portfolio, clinical and real-world data for therapies such as SKYRIZI and RINVOQ, FDA regulatory submissions and response letters, and medical-conference presentations in inflammatory bowel disease and other immune-mediated conditions.
Company news also covers pipeline spending, acquired in-process research and development, manufacturing capacity for medicines in core therapeutic areas, and investor conference appearances. AbbVie’s product references commonly include SKYRIZI, RINVOQ, Botox Therapeutic, Vraylar, Ubrelvy, Qulipta, Venclexta, Imbruvica and Elahere.
AbbVie has extended its collaboration with the University of Chicago through 2025 to bolster preclinical oncology research. This partnership has yielded insights into biomarkers and novel drug delivery strategies enhancing anti-tumor immune responses. The extension aims to further accelerate medical research in oncology, with AbbVie gaining exclusive licensing rights to certain discoveries. AbbVie emphasizes the collaboration's potential impact on public health and aims to leverage findings for developing innovative cancer therapies.
AbbVie (NYSE: ABBV) will participate in the Wolfe Research Healthcare Conference on November 17, 2021, at 8:30 a.m. Central time. Key executives including Dr. Michael Severino, Robert A. Michael, and Jeffrey R. Stewart will present at the event. A live audio webcast will be available on AbbVie's Investor Relations website, with an archived version accessible later the same day. AbbVie's mission focuses on delivering innovative medicines in various therapeutic areas, including immunology, oncology, and more.
AbbVie (NYSE: ABBV) reported promising results from post-hoc analyses of the Phase 3 SELECT-PsA 1 and SELECT-PsA 2 trials, demonstrating that upadacitinib (RINVOQ®) provided greater clinical responses for active psoriatic arthritis (PsA) patients with axial involvement compared to both placebo and HUMIRA® at 24 weeks. Specifically, 69.8% of patients on upadacitinib achieved clinically important improvement. Safety profiles were consistent with previous studies, with no new risks identified. Upadacitinib is currently under FDA review for PsA treatment.
Summary not available.
NORTH CHICAGO, Ill., Nov. 8, 2021 – Allergan, part of AbbVie (NYSE: ABBV), will present new analyses of VUITYTM (pilocarpine HCl) and DURYSTA® (bimatoprost) at the AAO 2021 Annual Meeting (Nov. 12-15). VUITY is the first FDA-approved eye drop for presbyopia, aiding nearly 128 million U.S. adults. DURYSTA aims to reduce intraocular pressure in glaucoma patients. Key presentations include pooled safety and efficacy data and real-world studies of glaucoma treatment. This reflects AbbVie's commitment to advancing eye care.
AbbVie presented integrated data from two Phase 3 trials, KEEPsAKE 1 and KEEPsAKE 2, showing that treatment with risankizumab (SKYRIZI) significantly improved signs and symptoms of psoriatic arthritis (PsA) after 24 weeks compared to placebo. Patients receiving risankizumab achieved an ACR20 response rate of 55.5% versus 31.3% for placebo. No new safety signals were reported, with serious treatment-emergent adverse events at 3.0% for risankizumab and 4.4% for placebo. Regulatory reviews for approval in the U.S. and EU are ongoing.
Genmab A/S (GMAB) announced several abstract presentations at the 63rd Annual ASH Meeting, showcasing the efficacy of epcoritamab (DuoBody®-CD3xCD20) for treating B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. Over 20 abstracts from Genmab and its partners, including AbbVie (ABBV) and Janssen, will be shared, highlighting clinical trial results. A virtual R&D Update and ASH Data Review is scheduled for December 14, focusing on these advancements in oncology.
AbbVie (NYSE: ABBV) is set to present nearly 30 abstracts at the upcoming American Society of Hematology (ASH) Annual Meeting, scheduled for December 11-14 in Atlanta, Georgia. Key studies include the Phase 2 CAPTIVATE and Phase 3 GLOW trials, which assess treatments for chronic lymphocytic leukemia (CLL) using ibrutinib and venetoclax. Additional research will cover various hematologic cancers, focusing on venetoclax's efficacy in CLL and multiple myeloma. The findings aim to advance care standards for patients with significant unmet medical needs.
AbbVie (NYSE: ABBV) will present new data on RINVOQ®, SKYRIZI®, and HUMIRA® at the ACR Convergence 2021, held virtually from November 3-9. This includes 38 abstracts focusing on rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Notable presentations highlight long-term safety and efficacy data for RINVOQ in rheumatoid arthritis, along with efficacy data for risankizumab in psoriatic arthritis. However, use of RINVOQ and risankizumab in psoriatic arthritis is not yet FDA-approved.
Allergan, a subsidiary of AbbVie (NYSE: ABBV), announced FDA approval for VUITY (pilocarpine HCl ophthalmic solution) 1.25% to treat presbyopia, affecting 128 million Americans. This marks VUITY as the first FDA-approved eye drop for this condition, providing rapid relief within 15 minutes and lasting up to 6 hours. The approval is based on two phase 3 studies (GEMINI 1 and GEMINI 2) showing significant improvement in near vision without distance vision loss. The most common side effects are headache and eye redness.